Navigation Links
Suzanne Gagnon, M.D. Joins Idis As Chief Medical Officer
Date:3/12/2013

PRINCETON, N.J., March 12, 2013 /PRNewswire/ -- Idis announced today the appointment of Suzanne Gagnon , M.D., as Chief Medical Officer.  Dr. Gagnon takes on responsibility for leading global medical affairs and providing strategic medical and regulatory leadership across all business divisions.  She will also oversee global quality assurance and compliance.

"We are delighted to have Suzanne join us at this exciting time in the global expansion of Idis. Successful managed access programs require alignment among all stakeholders, from R&D though commercial teams to the physicians treating patients," noted Natalie Douglas , CEO of Idis.  "Suzanne brings senior leadership to our team and a unique blend of industry expertise to our customers that will help guide development and implementation of programs that balance stakeholder requirements and effectively address the needs of patients."

The addition of the CMO role and appointment of Dr. Gagnon further strengthens Idis' offering in the US and enhances the Company's ability to deliver patient-centric programs that address the access challenges faced by patients, physicians and companies around the world. 

Dr. Gagnon has more than twenty years leading the medical, regulatory and safety aspects of pharmaceutical product development and has held senior management positions in both academia and in the pharmaceutical and CRO industries.  Formerly CMO and Executive Vice President at ICON Clinical Research for nearly ten years, Dr. Gagnon brings with her senior level experience in medical, regulatory and clinical research operations, as well as safety and risk management expertise.

Dr. Gagnon will be based at Idis' North American headquarters in Princeton, NJ.

About Idis
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world. 

Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product's lifecycle from pre-approval to market exit, and in times of unexpected production shortages.

The company's European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.

For more information about Idis please visit www.idispharma.com.

Contact: Christine Quern
Phone: +1 617 761 6791
Email  Christine.quern@fkhealth.com


'/>"/>
SOURCE Idis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Physician Joins Colorado Center for Reproductive Medicine
2. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
3. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
4. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
5. Natalie Douglas, CEO of Idis, Joins Global Genes
6. RARE Project Board of Directors
7. Breast Imaging Specialist Dr. Catherine D. Buhler Joins Radiologic Associates of Fredericksburg
8. Stephen Ondra, M.D., Joins Health Care Service Corporation As Enterprise Chief Medical Officer
9. Attorney Ellen Presby Joins The Nemeroff Law Firm In Dallas
10. Kevin Johnson Joins United Allergy Services Board Of Directors
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... July 5, 2017 Pace Analytical, a company of over 2,000 employees ... they have acquired ESC Lab Sciences, further solidifying their position as the top ... . ... President and CEO of Pace Analytical ... Sciences out of Mt Juliet, TN , enhances Pace Analytical,s ...
(Date:6/30/2017)... June 30, 2017 In vitro diagnostics market ... of May, at least ten diagnostic companies have successfully ... public offerings and a loan facility.  The size of ... $80 million.  Kalorama Information provides a monthly IVD ... Diagnostics Knowledge Center. ...
(Date:6/27/2017)... June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... specializing in the development of cannabinoid-based drugs, today announced ... Opening Bell in New York, NY ... its initial public offering (IPO) of American Depository Shares ... 2017. Dr. Elran Haber, Ph.D., Chief Executive ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set ... the FCPX timeline. This effect isolates horizontal and vertical lines of pixels and sorts ... a rotating or flipping animation and can be changed using a drop-down menu. Create ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, P.C. , ... announce their expansion to the Midwest with the establishment of the firm’s new ... Bell, and of counsels, John Peck and Robert Bruns, will establish and anchor ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of ... Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of medical ... Dr. Russell Horine serving as the clinic director and his son Dr. Lee Horine ...
(Date:7/20/2017)... ... 2017 , ... The Dermatology Clinic announced today the addition of Dr. Scott ... from LSU, graduating summa cum laude. He attended Emory University School of Medicine in ... Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship ...
Breaking Medicine News(10 mins):